Multiple endpoint comparisons favoured the rolapitant
group compared with the active control group. Although
some endpoints are interdependent (eg, no emesis is
part of the complete response endpoint), these endpoints
are used routinely in other similar clinical trials to assess
diff erent aspects of chemotherapy-induced nausea and
vomiting symptoms and are clinically meaningful.